mTOR inhibition in COVID‐19: A commentary and review of efficacy in RNA viruses
In this commentary, we shed light on the role of the mammalian target of rapamycin (mTOR) pathway in viral infections. The mTOR pathway has been demonstrated to be modulated in numerous RNA viruses. Frequently, inhibiting mTOR results in suppression of virus growth and replication. Recent evidence points towards modulation of mTOR in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We discuss the current literature on mTOR in SARS-CoV-2 and highlight evidence in support of a role for mTOR inhibitors in the treatment of coronavirus disease 2019.
Authors
- Sahar Lotfi‐Emran (ORCID: https://orcid.org/0000-0002-8650-6779)
- Rachel Morris (ORCID: https://orcid.org/0000-0002-1227-2420)
- Carolyn T. Bramante (ORCID: https://orcid.org/0000-0001-5858-2080)
- Anthony Charles (ORCID: https://orcid.org/0000-0001-7332-4354)
- Michael A. Puskarich (ORCID: https://orcid.org/0000-0001-6358-4670)
- Nicholas E. Ingraham (ORCID: https://orcid.org/0000-0002-0292-0594)
- David J. Odde (ORCID: https://orcid.org/0000-0001-7731-2799)
- Emily Zolfaghari (ORCID: https://orcid.org/0000-0001-7012-3645)
- Basil S. Karam
- Christopher J. Tignanelli
Institutions
- University of North Carolina at Chapel Hill (US)
Publication Details
- Journal
- UNC Libraries
- Published
- 2024-08-29
- DOI
- https://doi.org/10.17615/kcfx-6s16
- Primary Topic
- Animal Virus Infections Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Patient-Centered Outcomes Research Institute
- University of Minnesota
- Agency for Healthcare Research and Quality
- National Heart, Lung, and Blood Institute
- National Center for Advancing Translational Sciences